CO6290682A2 - Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c. - Google Patents
Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.Info
- Publication number
- CO6290682A2 CO6290682A2 CO10098657A CO10098657A CO6290682A2 CO 6290682 A2 CO6290682 A2 CO 6290682A2 CO 10098657 A CO10098657 A CO 10098657A CO 10098657 A CO10098657 A CO 10098657A CO 6290682 A2 CO6290682 A2 CO 6290682A2
- Authority
- CO
- Colombia
- Prior art keywords
- fusioned
- inhibiting
- compounds
- hepatitis virus
- triciclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a compuestos, composiciones y procedimientos para el tratamiento de infección por el virus de la hepatitis C (VHC). También se revelan composiciones farmacéuticas que contienen tales compuestos y procedimientos de uso de estos compuestos en el tratamiento de infección por VHC.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2827708P | 2008-02-13 | 2008-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6290682A2 true CO6290682A2 (es) | 2011-06-20 |
Family
ID=40581591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10098657A CO6290682A2 (es) | 2008-02-13 | 2010-08-11 | Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c. |
Country Status (28)
Country | Link |
---|---|
US (1) | US8147818B2 (es) |
EP (1) | EP2245027B1 (es) |
JP (1) | JP5455933B2 (es) |
KR (1) | KR101624365B1 (es) |
CN (1) | CN102143959B (es) |
AR (1) | AR070366A1 (es) |
AT (1) | ATE555109T1 (es) |
AU (1) | AU2009214997B2 (es) |
BR (1) | BRPI0908240A2 (es) |
CA (1) | CA2715559A1 (es) |
CL (1) | CL2009000324A1 (es) |
CO (1) | CO6290682A2 (es) |
CY (1) | CY1112999T1 (es) |
DK (1) | DK2245027T3 (es) |
EA (1) | EA018313B1 (es) |
ES (1) | ES2384911T3 (es) |
HK (1) | HK1143812A1 (es) |
HR (1) | HRP20120523T1 (es) |
IL (1) | IL207459A (es) |
MX (1) | MX2010008749A (es) |
NZ (1) | NZ587322A (es) |
PE (1) | PE20091381A1 (es) |
PL (1) | PL2245027T3 (es) |
PT (1) | PT2245027E (es) |
SI (1) | SI2245027T1 (es) |
TW (1) | TWI458482B (es) |
WO (1) | WO2009102633A1 (es) |
ZA (1) | ZA201005484B (es) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8303944B2 (en) * | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102245604A (zh) | 2008-12-23 | 2011-11-16 | 雅培制药有限公司 | 抗病毒化合物 |
EP2367824B1 (en) | 2008-12-23 | 2016-03-23 | AbbVie Inc. | Anti-viral derivatives of pyrimidine |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
US8242156B2 (en) * | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
UY32462A (es) * | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
MX2011008982A (es) | 2009-02-27 | 2011-09-15 | Enata Pharmaceuticals Inc | Inhibidores del virus de la hepatitis c. |
US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8101643B2 (en) * | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8507522B2 (en) | 2009-03-06 | 2013-08-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8796466B2 (en) * | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2011010905A (es) * | 2009-04-15 | 2011-11-01 | Abbott Lab | Compuestos antivirales. |
US9139569B2 (en) | 2009-05-12 | 2015-09-22 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
EP2857394A1 (en) | 2009-05-13 | 2015-04-08 | Gilead Pharmasset LLC | Antiviral compounds |
WO2010138791A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2010253790A1 (en) | 2009-05-29 | 2011-12-15 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
EP2337781B1 (en) * | 2009-06-11 | 2014-07-23 | AbbVie Bahamas Ltd. | Anti-viral compounds to treat hcv infection |
US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
AU2010274001A1 (en) | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
SG178952A1 (en) | 2009-09-04 | 2012-04-27 | Glaxosmithkline Llc | Chemical compounds |
US9156818B2 (en) * | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8927709B2 (en) * | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8759332B2 (en) * | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8703938B2 (en) * | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2011031934A1 (en) * | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
US8822700B2 (en) * | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
WO2011066241A1 (en) * | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
US20110137633A1 (en) * | 2009-12-03 | 2011-06-09 | Abbott Laboratories | Anti-viral compounds and methods of identifying the same |
EP2512480A4 (en) | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US8377980B2 (en) * | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
NZ600608A (en) * | 2009-12-18 | 2015-01-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
US20110152246A1 (en) * | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
US20130156731A1 (en) * | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EA201201031A1 (ru) | 2010-01-25 | 2013-02-28 | Энанта Фармасьютиклз, Инк. | Ингибиторы вируса гепатита с |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8178531B2 (en) * | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
US8623814B2 (en) * | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
CA2791630A1 (en) * | 2010-03-04 | 2011-09-09 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as inhibitors of hcv replication |
ES2558554T3 (es) * | 2010-03-09 | 2016-02-05 | Merck Sharp & Dohme Corp. | Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas |
AU2011232331A1 (en) | 2010-03-24 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of Flavivirus infections |
US9127021B2 (en) | 2010-04-09 | 2015-09-08 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
CA2803248A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
JP2013531011A (ja) | 2010-06-28 | 2013-08-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
AU2010358561B2 (en) * | 2010-08-04 | 2016-06-02 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2603080A4 (en) | 2010-08-12 | 2014-01-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
JP2013534249A (ja) | 2010-08-17 | 2013-09-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス科ウイルス感染の処置または予防のための化合物および方法 |
EP2616461A4 (en) * | 2010-08-26 | 2014-03-26 | Rfs Pharma Llc | POWERFUL AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS |
WO2012058125A1 (en) | 2010-10-26 | 2012-05-03 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
KR20190140486A (ko) * | 2010-11-17 | 2019-12-19 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
CN103649079B (zh) | 2010-12-22 | 2016-11-16 | Abbvie公司 | 丙型肝炎抑制剂及其用途 |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US9546160B2 (en) * | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
JP5669984B2 (ja) | 2011-05-18 | 2015-02-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | 5−アザスピロ[2.4]ヘプタン−6−カルボン酸およびその誘導体の製造方法 |
WO2012175581A1 (en) | 2011-06-24 | 2012-12-27 | F. Hoffmann-La Roche Ag | Antiviral compounds |
AU2012286853A1 (en) | 2011-07-26 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Thiophene compounds |
WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
WO2013021344A1 (en) | 2011-08-08 | 2013-02-14 | Lupin Limited | Imidazole derivatives as antiviral agents |
SG10201606446XA (en) | 2011-08-08 | 2016-09-29 | Lupin Ltd | Antiviral compounds with a fused tricyclic ring |
WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
PL2709613T5 (pl) | 2011-09-16 | 2020-12-14 | Gilead Pharmasset Llc | Metody leczenia hcv |
PL2635588T3 (pl) * | 2011-11-16 | 2015-10-30 | Gilead Pharmasset Llc | Skondensowane imidazoliloimidazole jako związki antywirusowe |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2013118097A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
CN104302639B (zh) | 2012-04-25 | 2017-03-29 | 施万生物制药研发Ip有限责任公司 | 作为c型肝炎病毒抑制剂的哌嗪‑哌啶化合物 |
CN104302636B (zh) | 2012-04-25 | 2017-03-29 | 施万生物制药研发Ip有限责任公司 | C型肝炎病毒抑制剂 |
US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
WO2014134251A1 (en) | 2013-02-28 | 2014-09-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
WO2016141890A1 (en) * | 2015-03-12 | 2016-09-15 | Sunshine Lake Pharma Co., Ltd. | Compounds as hepatitis c virus inhibitors and pharmaceutical uses thereof |
WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
AU2019222644B2 (en) | 2018-02-13 | 2021-04-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP7105359B2 (ja) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP2022510407A (ja) | 2018-12-04 | 2022-01-26 | ブリストル-マイヤーズ スクイブ カンパニー | 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5654451B1 (en) * | 1993-01-14 | 2000-02-22 | Magainin Pharma | Amino acids and peptides having modified c-terminals and modified n-terminals |
CA2153987A1 (en) | 1993-01-14 | 1994-07-21 | U. Prasad Kari | Amino acids and peptides having modified terminals |
US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
GB2438802A (en) | 2005-02-28 | 2007-12-05 | Univ Rockefeller | Structure of the hepatitis C virus NS5A protein |
US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
DE602006016313D1 (de) | 2005-09-16 | 2010-09-30 | Arrow Therapeutics Ltd | Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c |
WO2007058384A1 (en) | 2005-11-17 | 2007-05-24 | Osaka University | Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same |
SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
BRPI0712806A2 (pt) | 2006-05-30 | 2012-10-23 | Arrow Therapeutics Ltd | uso de um composto, derivado de bifenila ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, produto, e, método para melhorar uma infecção por hepatite c em um paciente |
US7745636B2 (en) * | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8303944B2 (en) * | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2672737A1 (en) | 2006-12-20 | 2008-11-06 | Abbott Laboratories | Anti-viral compounds |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
-
2009
- 2009-01-23 US US12/358,587 patent/US8147818B2/en active Active
- 2009-02-06 NZ NZ587322A patent/NZ587322A/en not_active IP Right Cessation
- 2009-02-06 EP EP09709849A patent/EP2245027B1/en active Active
- 2009-02-06 EA EA201001273A patent/EA018313B1/ru not_active IP Right Cessation
- 2009-02-06 MX MX2010008749A patent/MX2010008749A/es active IP Right Grant
- 2009-02-06 ES ES09709849T patent/ES2384911T3/es active Active
- 2009-02-06 CN CN200980112993.9A patent/CN102143959B/zh not_active Expired - Fee Related
- 2009-02-06 KR KR1020107020306A patent/KR101624365B1/ko not_active IP Right Cessation
- 2009-02-06 JP JP2010546841A patent/JP5455933B2/ja not_active Expired - Fee Related
- 2009-02-06 AT AT09709849T patent/ATE555109T1/de active
- 2009-02-06 WO PCT/US2009/033380 patent/WO2009102633A1/en active Application Filing
- 2009-02-06 PT PT09709849T patent/PT2245027E/pt unknown
- 2009-02-06 AU AU2009214997A patent/AU2009214997B2/en not_active Ceased
- 2009-02-06 DK DK09709849.5T patent/DK2245027T3/da active
- 2009-02-06 SI SI200930300T patent/SI2245027T1/sl unknown
- 2009-02-06 PL PL09709849T patent/PL2245027T3/pl unknown
- 2009-02-06 CA CA2715559A patent/CA2715559A1/en not_active Abandoned
- 2009-02-06 BR BRPI0908240A patent/BRPI0908240A2/pt not_active IP Right Cessation
- 2009-02-11 PE PE2009000200A patent/PE20091381A1/es not_active Application Discontinuation
- 2009-02-12 AR ARP090100503A patent/AR070366A1/es unknown
- 2009-02-12 CL CL2009000324A patent/CL2009000324A1/es unknown
- 2009-02-13 TW TW098104731A patent/TWI458482B/zh not_active IP Right Cessation
-
2010
- 2010-07-30 ZA ZA2010/05484A patent/ZA201005484B/en unknown
- 2010-08-08 IL IL207459A patent/IL207459A/en not_active IP Right Cessation
- 2010-08-11 CO CO10098657A patent/CO6290682A2/es active IP Right Grant
- 2010-11-08 HK HK10110404.7A patent/HK1143812A1/xx not_active IP Right Cessation
-
2012
- 2012-06-21 HR HRP20120523AT patent/HRP20120523T1/hr unknown
- 2012-07-20 CY CY20121100642T patent/CY1112999T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6290682A2 (es) | Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c. | |
CO6561788A2 (es) | Inhibidores del virus de la hepatitis c | |
CO6400192A2 (es) | Inhibidores del virus de la hepatitis c | |
BR112012011100A2 (pt) | compostos inibidores do vírus da hepatite, composição e uso dos mesmos | |
CO6440581A2 (es) | Inhibidores del virus de la hepatitis c | |
BR112013020042A2 (pt) | inibidores de vírus da hepatite c | |
EA201001275A1 (ru) | Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с | |
BR112013002729A2 (pt) | inibidores de vírus de hepatite c | |
BR112013003101A2 (pt) | inibidores do vírus da hepatite c | |
EA201390538A1 (ru) | Противовирусные соединения | |
DK2250163T3 (da) | Hepatitis C-virusinhibitorer | |
CU23787B7 (es) | Compuestos macrocíclicos como inhibidores de la replicación viral | |
NO20090453L (no) | Hepatitt C Virusinhibitorer | |
MX2011006631A (es) | Inhibidores de proteasa ns3 del virus hcv. | |
UY34066A (es) | Inhibidores del virus de la hepatitis c | |
MX354676B (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv). | |
BR112014013972A2 (pt) | inibidores de hcv nssa | |
BR112014015582A2 (pt) | compostos antivirais | |
CO6290680A2 (es) | Inhibidores de virus de la hepatitis c | |
UA113048C2 (xx) | Противірусні сполуки | |
MX2012004922A (es) | Compuesto de 5,6-dihidro-1h-piridin-2-ona deuterados. | |
CL2012001269A1 (es) | Compuestos derivados de bi-imidazol di-sustituidos; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar infecciones por virus de hepatitis c (vhc). | |
CY1114249T1 (el) | Αναστολεις του ιου ηπατιτιδας c | |
CO6321231A2 (es) | Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatitis c | |
UA108904C2 (xx) | Противірусні сполуки |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |